Wong, WPSScott, DWSaafi, ELFerreira, AChoong, YeeCooper, Garth2012-05-272008DIABETES 57(10):2737-2744 01 Oct 20080012-1797http://hdl.handle.net/2292/18631OBJECTIVES—We sought to 1) Determine whether solublemisfolded amylin or insoluble-fibrillar amylin may cause or result from diabetes in human amylin transgenic mice and 2) determine the role, if any, that insulin resistance might play in these processes. RESEARCH DESIGN AND METHODS—We characterized the phenotypes of independent transgenic mouse lines that display pancreas-specific expression of human amylin or a nonaggregating homolog, human amylin, in an FVB/n background. RESULTS—Diabetes occurred in hemizygous human amylin transgenic mice from 6 weeks after birth. Glucose tolerance was impaired during the mid- and end-diabetic phases, in which progressive ß-cell loss paralleled decreasing pancreatic and plasma insulin and amylin. Peripheral insulin resistance was absent because glucose uptake rates were equivalent in isolated soleus muscles from transgenic and control animals. Even in advanced diabetes, islets lacked amyloid deposits. In islets from nontransgenic mice, glucagon and somatostatin cells were present mainly at the periphery and insulin cells were mainly in the core; in contrast, all three cell types were distributed throughout the islet in transgenic animals. human amylin transgenic mice developed neither ß-cell degeneration nor glucose intolerance. CONCLUSIONS—Overexpression of fibrillogenic human amylin in these human amylin transgenic mice caused ß-cell degeneration and diabetes through mechanisms independent from both peripheral insulin resistance and islet amyloid. These findings are consistent with ß-cell death evoked by misfolded but soluble cytotoxic species, such as those formed by human amylin in vitro.Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htmJournal Article10.2337/db06-1755Copyright: American Diabetes Association18633116http://purl.org/eprint/accessRights/RestrictedAccess1939-327X